GH1 and meningioma: Of 10,786 patients recorded as treated with r-hGH in the five study countries, 257 had to be excluded from analysis because of lack of permission for cancer incidence follow-up or lack of data, and 126 because of an underlying diagnosis at high risk of cancer or an underlying diagnosis of meningioma as the reason for GH treatment.